
Efficient Dlx2-mediated astrocyte-to-neuron conversion and inhibition of neuroinflammation by NeuroD1
Brief intro:
- Author: Min-Hui Liu, Yu-Ge Xu, Xiao-Ni Bai, Jian-Hua Lin, Zong-Qin Xiang, Tao Wang, Liang Xu, Wen Li, Gong Chen
- Journal: BioRxiv
- Doi: https://www.doi.org/10.1101/2022.07
- Publication Date: 2022 Jul 12
Products/Services used in the paper
Quotation shows PackGene:hGFAP promoter used in the AAV vectors is the synthetic 681- bp gfaABC1D. The construction of pAAV GFAP::GFP, GFAP::Dlx2-P2A-GFP, GFAP::NeuroD1-P2A-GFP, the following AAV9 virus package, purification with iodixanol and subsequent concentration, as well as virus titration were produced by PackGene® Biotech, LLC (Guangzhou, China).
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Both adult male and female wild-type C57BL/6J mice (Guangdong Medical Laboratory Animal Center) and Aldh1l1::CreERT2 transgenic mice (The Jackson Laboratory, RRID:IMSR_JAX:031008) at 2-5 months of age were recruited in the experiments.
Abstract
In vivo astrocyte-to-neuron (AtN) conversion induced by overexpression of neural transcriptional factors has great potential for neural regeneration and repair. Here, we demonstrate that a single neural transcriptional factor Dlx2 converts mouse striatal astrocytes into neurons in a dose-dependent manner. Lineage-tracing studies in Aldh1l1-CreERT2 mice confirm that Dlx2 can convert striatal astrocytes into DARPP32+ and Ctip2+ medium spiny neurons (MSNs). Time-course studies reveal a gradual conversion from astrocytes to neurons in 1 month, with a distinct intermediate state in-between astrocytes and neurons. Interestingly, when Dlx2-infected astrocytes start to lose astrocytic markers, the other local astrocytes proliferate to maintain astrocytic level in the converted areas. Unexpectedly, while Dlx2 efficiently reprograms astrocytes into neurons in the grey matter striatum, it also induces partial reprogramming of astrocytes in the white matter corpus callosum. Such partial reprogramming of white matter astrocytes is associated with neuroinflammation, which can be essentially suppressed by the addition of NeuroD1. Our results highlight the importance of investigating AtN conversion both in the grey matter and white matter in order to thoroughly evaluate therapeutic potentials. This study also unveils a critical role of anti-inflammation by NeuroD1 during AtN conversion.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
